Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

NCT01514188 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Soft Tissue Sarcoma
Locally Advanced Soft Tissue Sarcoma
Unresectable Soft Tissue Sarcoma

Interventions

DRUG: INNO-206
DRUG: Doxorubicin

Sponsor

ImmunityBio, Inc.